0

Category: Type 2 Diabetes

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

Results of a recent analysis that compared the efficacy, safety, and metabolic effects of the angiotensin-receptor blocker (ARB) azilsartan medoxomil to valsartan and olmesartan separately in patients with prediabetes and type 2 diabetes found that azilsartan (80 mg) lowered systolic blood pressure to a significantly greater degree than either valsartan or olmesartan. Read more

“Burst” Exercise Leads to Greater Cardiometabolic Improvements in Patients with Type 2 Diabetes

Researchers studied 76 patients with type 2 diabetes randomly assigned to either 30 minutes of exercise 5 days per week at 65% of their target heart rate, or 10 minutes of exercise 3 times per day, 5 days per week at 85% of their target heart rate. The “burst” exercisers experienced a 2.3-fold greater improvement in HbA1c and a 3-fold reduction in BMI, along with greater improvements in LDL-C, HDL-C, and triglyceride levels and stronger cardiac fitness, which was measured by stress testing.

It isn’t clear why burst exercise resulted in more significant cardiometabolic improvements than longer, low-intensity exercise. Lead study author Avinash Pandey suggested it may be due to higher intensity exercise using energy in a different way. “We are hoping to continue looking at burst exercise and sustained energy in larger and more diverse patient populations. With further study, burst exercise may become a viable alternative to the current standard of care of low-intensity, sustained exercise for diabetes rehabilitation,” he said. Read more